Mitrix Bio proposes studying mitochondria from donor platelets to fight infections
Mitrix Bio proposes studying mitochondria from donor platelets to fight infections
On November 7, biotechnology company Mitrix Bio invited scientists and physicians to independently replicate its experiments. The company proposes using blood services to obtain mitochondria for research, with isolation methods already described in scientific publications.
When activated, platelets release mitochondria, both freely and enclosed in membrane vesicles. Researchers found them in transfusion bags as early as 2014. Mitrix calls the mitochondria-containing vesicles Mitlets. The company proposes using a centrifuge to separate a mixture containing these particles from the platelets themselves and study its effects.
Mitrix hopes donor mitochondria will help immune cells fight infection. In cell experiments in 2023, mouse immune cells took up the particles, followed by a temporary increase in oxygen consumption associated with energy production. To test the role of the mitochondria themselves, the researchers inhibited their function before adding the particles to neutrophils, a type of immune cell. The neutrophils continued to take up the particles, but the increase in oxygen consumption disappeared.
A 2023 preprint describes a pilot experiment in mice that tested the mixture's effects on infection in a whole organism. Material from two-month-old donors was administered to 13-month-old mice, starting one day before an infection that induced sepsis, a life-threatening response to infection. Compared with the control group, the authors observed fewer bacteria in the blood and higher survival during the first week. The effect waned within a few days of the last administration.
Mitrix argues that a simple, publicly available process is difficult to fund because investors have fewer opportunities to profit from exclusive rights to sell such a product. The company therefore proposes sharing the published methods and having other laboratories and hospitals independently test the findings. In its August press release, Mitrix offers an open license to qualified medical professionals, provided they accept responsibility for the outcomes. In 2023, Mitrix's own patent application was published, covering the isolation of a mitochondria-containing particle mixture from platelets and its administration to treat sepsis.
Emergency physician Lance Becker, who is involved in the program, proposes the following in the same release:
We want to establish a small network of specialized research emergency departments.
These departments plan to develop the capability to prepare and administer the mixture from donor platelets. Small human studies would assess its safety and the feasibility of performing the procedure in clinical settings.
- https://x.com/PathfinderEq/status/2119042756052201827
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4260364/
- https://onlinelibrary.wiley.com/doi/full/10.1111/trf.17524
- https://www.biorxiv.org/content/10.1101/2023.09.08.556161v2
- https://mitrix.bio/wp-content/uploads/2026/08/Mitrix-Sepsis-press-release_Aug-20-2026-1.pdf
- https://patents.google.com/patent/CA3256682A1/en